IQVIA Holdings stock (US46266C1053): NYSE healthcare data specialist steady after recent earnings

IQVIA Holdings shares traded broadly steady in recent US sessions, with the New York-listed stock changing hands at about USD 182 at the close on 05/29/2026 on the NYSE, according to MarketBeat as of 05/29/2026. The United States-based healthcare data and services group remains closely watched after its latest quarterly earnings update earlier in the spring, which provided fresh insight into demand for analytics and clinical research from global life sciences customers.

The stock price of IQVIA Holdings on the NYSE was quoted at USD 182.03 at the regular close on 05/29/2026, representing a modest gain of 0.52% for that session, while after-hours trading indicated USD 182.70, based on data from MarketBeat as of 05/29/2026. For context, that leaves the company with a market capitalization of roughly USD 30.4 billion and a price/earnings multiple around the low-20s on recent figures, according to trading information compiled by Robinhood as of late May 2026, anchoring the stock firmly within the large-cap US healthcare services segment.

The stock traded at 182.03 USD on 05/29/2026 on the New York Stock Exchange, according to MarketBeat as of 05/29/2026.

As of: 05/31/2026

By the editorial team - specialized in equity coverage.

IQVIA Holdings: core business model

IQVIA Holdings operates as a global partner to the life sciences industry, combining large-scale healthcare data assets with technology platforms and contract research capabilities to support drug development, commercialization, and real-world evidence generation for pharmaceutical, biotech, and medical device companies.

Chart technicals and 52-week range

From a technical perspective, IQVIA Holdings has traded in a broad band over the past 12 months, with the NYSE-quoted shares fluctuating around their current level of just above USD 180 and remaining sensitive to quarterly earnings releases and updates on life sciences spending, as reflected in trading data from MarketBeat as of 05/29/2026. While detailed chart indicators such as relative strength or moving averages can shift quickly with market conditions, the recent price behavior highlights how investors continue to calibrate expectations for medium-term growth in contract research and data analytics against valuation multiples in the US healthcare services space.

At the current quotation around USD 182 on the New York Stock Exchange, IQVIA Holdings trades at a valuation in the low-20s on a price/earnings basis using recent earnings metrics, according to figures compiled by Robinhood as of late May 2026. Against this backdrop, chart-oriented observers may monitor whether the share price can sustain levels above recent consolidation areas near its current trading zone or whether shifts in sentiment around healthcare research spending could trigger a test of lower support regions within the observed one-year range.

Conclusion

IQVIA Holdings remains an actively traded US healthcare data and clinical research stock on the New York Stock Exchange, with its share price around USD 182 at the end of May 2026 and investors continuing to factor in its most recent quarterly earnings and outlook. The current technical picture, with the stock hovering close to the midpoint of its observed one-year range, underscores how sentiment is being shaped by expectations for life sciences research spending and demand for data-driven services. How these fundamental drivers evolve relative to the companys valuation metrics and peers across US healthcare services is likely to remain central to future trading patterns in the shares.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.